For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Research Peptide Timeline

From the first synthetic peptide hormones to the 2026 FDA compounding reviews: the key dates behind every compound in the Kalibra Labs catalog, each linked to its full reference page.

  1. 1906Arthur Harden and William John Young discover the coenzyme now called NAD+ in yeast juice NAD+ →
  2. 1906Henry Dale reports uterine-contracting activity of posterior pituitary extract, the first observation of oxytocin’s action Oxytocin →
  3. 1921Frederick Gowland Hopkins isolates and names glutathione at Cambridge L-Glutathione →
  4. 1929Glutathione's tripeptide structure is established by Hopkins and, independently, by Edward C. Kendall's team L-Glutathione →
  5. 1929Harden and Hans von Euler-Chelpin share the Nobel Prize in Chemistry NAD+ →
  6. 1953Vincent du Vigneaud’s group determines the structure of oxytocin and reports the first synthesis of a peptide hormone Oxytocin →
  7. 1955Du Vigneaud receives the Nobel Prize in Chemistry, in part for the synthesis of oxytocin Oxytocin →
  8. 1957Salmon and Daughaday describe 'sulfation factor', later identified as IGF-1 IGF-1 LR3 →
  9. 1966Allan Goldstein and Abraham White name the thymus extract factor "thymosin" Thymosin Alpha-1 →
  10. 1970Tuftsin, the parent peptide of Selank, discovered by Victor Najjar's group Selank →
  11. 1970Sami Said and Viktor Mutt report isolating vasoactive intestinal peptide (VIP) from porcine small intestine VIP (vasoactive intestinal peptide) →
  12. 1971Schally's group determines the sequence of porcine LH/FSH-releasing hormone (GnRH, gonadorelin) Gonadorelin →
  13. 1973Loren Pickart isolates the GHK tripeptide from human plasma at UCSF GHK-Cu →
  14. 1974Morozov and Khavinson publish their first thymus-extract paper in Leningrad Thymalin →
  15. 1974Full 28-amino-acid sequence of porcine VIP published by Mutt and Said VIP (vasoactive intestinal peptide) →
  16. 1977DSIP sequence published by Schoenenberger and Monnier at the University of Basel DSIP →
  17. 1977GHK sequence published as glycyl-histidyl-lysine GHK-Cu →
  18. 1977Guillemin and Schally share the Nobel Prize in Physiology or Medicine for brain peptide hormones Gonadorelin →
  19. 1977Thymosin alpha-1 isolated and sequenced by Goldstein's group Thymosin Alpha-1 →
  20. 1980University of Arizona researchers describe [Nle4, D-Phe7]-alpha-MSH, later named Melanotan I and then afamelanotide Melanotan I (afamelanotide) →
  21. 1981Goldstein's laboratory publishes the complete sequence of thymosin beta-4 TB-500 →
  22. 1982FDA approves Factrel (gonadorelin hydrochloride), later discontinued Gonadorelin →
  23. 1982Human GHRH isolated by Salk Institute teams of Roger Guillemin and Wylie Vale; GHRH(1-29), later sermorelin, reported active Sermorelin →
  24. 1982Thymalin reported as a new immunoregulatory preparation Thymalin →
  25. 1983USSR patent priority date for the tuftsin analog later named Selank Selank →
  26. 1984GHRP-6 reported by Cyril Bowers' team at Tulane University GHRP-6 →
  27. 1984James M. Lipton's team publishes on the alpha-MSH tripeptide KPV; patent priority date KPV →
  28. 1986Amylin identified by Per Westermark's group (Uppsala) and independently by Garth Cooper (Oxford), 1986–87 Cagrilintide →
  29. 1987Lipotec, later developer of SNAP-8, founded in Gavà, Spain SNAP-8 →
  30. 1987Follistatin isolated from porcine ovarian follicular fluid by Guillemin’s team at the Salk Institute Follistatin →
  31. 1989Priority date of the first Body Protection Compound (BPC) patent by Sikirić and colleagues, University of Zagreb BPC-157 →
  32. 1989FDA approves Lutrepulse (gonadorelin acetate), later discontinued Gonadorelin →
  33. 1989University of Arizona chemists publish the cyclic lactam alpha-MSH designs that led to Melanotan II Melanotan II →
  34. 1990FDA approves sermorelin (Geref) as a diagnostic agent Sermorelin →
  35. 1990Ebewe Pharma files the priority application for its European patent on the Cerebrolysin peptide mixture Cerebrolysin →
  36. 1990Follistatin identified as an activin-binding protein Follistatin →
  37. 1992Gensia files a U.S. new drug application for acadesine (AICAR) as Arasine; it was never approved AICAR →
  38. 1992Vladimir Khavinson founds the St. Petersburg Institute of Bioregulation and Gerontology Cartagen →
  39. 1992CSIRO Adelaide publishes the Long IGF-I analogs, including Long R3 IGF-I (IGF-1 LR3) IGF-1 LR3 →
  40. 1993First overview paper on BPC and the stomach-stress-organoprotection hypothesis published BPC-157 →
  41. 1994Semax first registered as a medicine in Russia Semax →
  42. 1995Corton, Hardie and colleagues describe AICAR as a tool to activate AMPK in intact cells AICAR →
  43. 1995Agerberth, Gudmundsson, Boman and colleagues report FALL-39, the precursor sequence of human cathelicidin LL-37 LL-37 →
  44. 1996KiSS-1 gene identified at Penn State College of Medicine, Hershey, as a melanoma metastasis suppressor Kisspeptin-10 →
  45. 1996Mature 37-amino-acid LL-37 peptide described in granulocytes LL-37 →
  46. 1996Goldspink laboratory (London) clones the IGF-1 isoform later named mechano growth factor (MGF) MGF (Mechano Growth Factor) and PEG-MGF →
  47. 1996NeuroSearch files the priority application for the tropane-derivative patent covering tesofensine (NS2330) Tesofensine →
  48. 1998Bowers predicts an unidentified natural hormone acting at the GHRP receptor GHRP-6 →
  49. 1998Ipamorelin first described by Raun and colleagues at Novo Nordisk, Denmark Ipamorelin →
  50. 1998IUPHAR names the VIP and PACAP receptors VPAC1, VPAC2 and PAC1 VIP (vasoactive intestinal peptide) →
  51. 1999Vladimir Khavinson files the patent on the tetrapeptide epitalon (Ala-Glu-Asp-Gly) Epitalon →
  52. 1999Ghrelin identified as the natural ligand of the growth hormone secretagogue receptor (Kojima, Kangawa) GHRP-6 →
  53. 1999Second Russian patent filed for Selank in an anxiety-related research program Selank →
  54. 2000AOD-9604 first described by F.M. Ng and colleagues at Monash University AOD-9604 →
  55. 2000Theratechnologies granted U.S. patent on GRF analogs (Brazeau and Gravel), the line that led to tesamorelin Tesamorelin →
  56. 2000Novo Nordisk scientists publish the acylated GLP-1 derivative chemistry behind liraglutide Liraglutide →
  57. 2001GPR54 (KISS1R) identified as the receptor for kisspeptins Kisspeptin-10 →
  58. 2001Pincus and Michl’s group at SUNY Downstate reports penetratin-linked p53 peptides, including the sequence later named PNC-27 PNC-27 →
  59. 2003GPR54 loss-of-function variants linked to absent puberty by two independent groups Kisspeptin-10 →
  60. 2003Synthetic actin-binding fragment of thymosin beta-4, the basis of TB-500, studied in mice TB-500 →
  61. 2004Adipotide (prohibitin-targeting peptide) first reported by Kolonin, Pasqualini and Arap at M.D. Anderson Adipotide →
  62. 2004Patent priority for Cardiogen, the tetrapeptide Ala-Glu-Asp-Arg (AEDR), by Vladimir Khavinson and colleagues Cardiogen →
  63. 2004Charles Brenner's group identifies nicotinamide riboside as an NAD+ precursor NAD+ →
  64. 2004Szeto, Schiller and colleagues publish the first paper on the mitochondria-targeted SS peptides, including SS-31 SS-31 (elamipretide) →
  65. 2005ConjuChem (Montreal) publishes CJC-1295, an albumin-binding GHRH(1-29) analog CJC-1295 →
  66. 2006Priority dates of the Khavinson patents on the cartilage tripeptide AED and a calf-cartilage peptide complex Cartagen →
  67. 2006ConjuChem halts its phase 2 CJC-1295 trial after a participant death (July) CJC-1295 →
  68. 2006Russian patent application for the tripeptide Glu-Asp-Arg (later called pinealon) filed by Khavinson and colleagues Pinealon →
  69. 2007Metabolic Pharmaceuticals ends AOD-9604 obesity program after OPTIONS trial AOD-9604 →
  70. 2007FDA issues a warning letter over the sale of Melanotan II as an unapproved new drug Melanotan II →
  71. 2008ARA-290 (cibinetide), an 11-amino-acid peptide from erythropoietin helix B, described by Brines, Cerami and colleagues ARA-290 (cibinetide) →
  72. 2008University of Münster team studies KPV in mouse models of inflammatory bowel disease KPV →
  73. 2008Geref (sermorelin) discontinued in the U.S. Sermorelin →
  74. 2010U.S. Patent 7,662,789 on the AEDR heart peptide granted Cardiogen →
  75. 2010Spadin, the parent peptide of PE-22-28, reported by a CNRS team as a TREK-1 blocker PE-22-28 →
  76. 2010FDA approves tesamorelin as Egrifta (10 Nov) Tesamorelin →
  77. 2010First Cochrane review of Cerebrolysin research in acute ischemic stroke published Cerebrolysin →
  78. 2010FDA approves liraglutide as Victoza for type 2 diabetes (25 Jan 2010) Liraglutide →
  79. 2010PNC-27 proposed to bind HDM-2 in cell membranes (PNAS); added to MeSH as a supplementary concept PNC-27 →
  80. 2011Adipotide primate study published in Science Translational Medicine Adipotide →
  81. 2011FDA grants ARA-290 orphan designation for neuropathic pain in sarcoidosis (sponsor Araim Pharmaceuticals) ARA-290 (cibinetide) →
  82. 2011First English-language study of pinealon published in Rejuvenation Research by the Khavinson group Pinealon →
  83. 2011Zealand Pharma licenses its glucagon/GLP-1 dual agonists, the program that produced survodutide, to Boehringer Ingelheim Survodutide →
  84. 2012RED-CABG trial of acadesine, stopped early for futility, published in JAMA AICAR →
  85. 2012Lubrizol acquires Lipotec, maker of SNAP-8 SNAP-8 →
  86. 2012European marketing application for tesamorelin withdrawn Tesamorelin →
  87. 2013FDA determines Geref was not withdrawn for safety or effectiveness reasons Sermorelin →
  88. 2013Washington State University researchers describe dihexa, a modified dipeptide derived from angiotensin IV; US Patent 8,598,118 granted Dihexa →
  89. 2014Helsinn's phase 2 ipamorelin study in postoperative ileus published; primary endpoint not met Ipamorelin →
  90. 2014European Commission authorizes Clinuvel’s Scenesse (afamelanotide implant) for erythropoietic protoporphyria Melanotan I (afamelanotide) →
  91. 2014Saniona acquires tesofensine from NeuroSearch Tesofensine →
  92. 2015MOTS-c described by Changhan Lee and Pinchas Cohen at USC in Cell Metabolism MOTS-c →
  93. 2015Novo Nordisk publishes the discovery of semaglutide, a once-weekly GLP-1 analogue Semaglutide →
  94. 20175-Amino-1MQ's quinolinium series first described as NNMT inhibitors by Neelakantan, Watowich and colleagues at UTMB 5-Amino-1MQ →
  95. 2017Peter de Keizer's team at Erasmus MC publishes FOXO4-DRI in Cell FOXO4-DRI →
  96. 2017Review summarizes hexarelin's cardiac research and its interaction with the CD36 receptor Hexarelin →
  97. 2017PE-22-28 first described as a shortened spadin analog by CNRS researchers PE-22-28 →
  98. 2017FDA approves semaglutide as Ozempic for type 2 diabetes Semaglutide →
  99. 2018Cleara Biotech launches to develop FOXO4-based peptides FOXO4-DRI →
  100. 2018Chugai licenses its oral non-peptide GLP-1 receptor agonist OWL833 (orforglipron) to Eli Lilly Orforglipron →
  101. 2018Eli Lilly publishes the discovery of LY3298176 (tirzepatide), a dual GIP/GLP-1 receptor agonist Tirzepatide →
  102. 2019Adipotide phase 1 trial terminated; development later listed as discontinued Adipotide →
  103. 2019Eli Lilly licenses mazdutide (then OXM3) to Innovent Biologics for development in China Mazdutide →
  104. 2019FDA approves Scenesse (afamelanotide implant) for adults with erythropoietic protoporphyria Melanotan I (afamelanotide) →
  105. 2019FDA approves bremelanotide (PT-141) as Vyleesi, developed by Palatin Technologies PT-141 (bremelanotide) →
  106. 2020Cryo-EM structure of LY3502970 (orforglipron) bound to the GLP-1 receptor published in PNAS Orforglipron →
  107. 2021Novo Nordisk publishes the design of cagrilintide, a long-acting amylin analogue Cagrilintide →
  108. 2021JPET places expressions of concern on four papers from the dihexa developers’ laboratory Dihexa →
  109. 2022U.S. Patent 11,401,243 on quinoline-derived NNMT inhibitors granted to the University of Texas System 5-Amino-1MQ →
  110. 2022Eli Lilly publishes the discovery of LY3437943 (retatrutide), a GIP, GLP-1 and glucagon triple receptor agonist Retatrutide →
  111. 2022Discovery and preclinical pharmacology of survodutide (BI 456906) published Survodutide →
  112. 2022FDA approves tirzepatide as Mounjaro for type 2 diabetes (13 May 2022) Tirzepatide →
  113. 2023FDA places GHRP-2 and GHRP-6 in Category 2 for outsourcing-facility compounding GHRP-2 →
  114. 2023FDA places ipamorelin in Category 2 for outsourcing-facility compounding Ipamorelin →
  115. 2023CohBar suspends development of MOTS-c analog CB4211 MOTS-c →
  116. 2023Palatin Technologies completes the sale of Vyleesi to Cosette Pharmaceuticals PT-141 (bremelanotide) →
  117. 2023SLU-PP-332 first fully described as a synthetic ERRα/β/γ agonist by Burris, Billon and colleagues (ACS Chemical Biology) SLU-PP-332 →
  118. 2023Boehringer Ingelheim launches the Phase III SYNCHRONIZE program for survodutide Survodutide →
  119. 2023FDA approves tirzepatide as Zepbound for chronic weight management (8 Nov 2023) Tirzepatide →
  120. 2024FDA PCAC votes 12–0 against adding AOD-9604 to the 503A bulks list (4 Dec) AOD-9604 →
  121. 2024Vladimir Khavinson, developer of the peptide bioregulator concept, dies Cartagen →
  122. 2024FDA's PCAC votes 17-4 against adding thymosin alpha-1 to the compounding bulks list Thymosin Alpha-1 →
  123. 2024FDA approves the first generic liraglutide referencing Victoza (23 Dec 2024) Liraglutide →
  124. 2024FDA declares the tirzepatide injection shortage resolved (19 Dec 2024) Tirzepatide →
  125. 2025Novo Nordisk submits CagriSema (cagrilintide plus semaglutide) to FDA (18 Dec) Cagrilintide →
  126. 2025FDA grants accelerated approval to elamipretide (SS-31) as Forzinity for Barth syndrome SS-31 (elamipretide) →
  127. 2025FDA approves Egrifta WR, a new tesamorelin formulation (March) Tesamorelin →
  128. 2025China’s NMPA approves mazdutide, the first approved dual GCG/GLP-1 receptor agonist, in June; a second indication follows in September Mazdutide →
  129. 2025Lilly reports the first Phase 3 trial of retatrutide, TRIUMPH-4 (11 Dec 2025) Retatrutide →
  130. 2025FDA declares the semaglutide injection shortage resolved (21 Feb 2025) Semaglutide →
  131. 2025Medix resubmits its tesofensine marketing application to Mexico’s COFEPRIS; still under review as of August 2026 Tesofensine →
  132. 2026FDA advisory committee votes 8–6–1 on BPC-157 compounding; no final FDA decision as of 22 Oct 2026 BPC-157 →
  133. 2026FDA's PCAC votes 7-4 to add epitalon to the 503A compounding bulks list; final FDA decision pending Epitalon →
  134. 2026FDA removes injectable GHK-Cu from its Category 2 compounding list (April) GHK-Cu →
  135. 2026FDA advisory committee votes 8–6–1 on KPV compounding against FDA staff's proposal; no final decision as of 22 Oct 2026 KPV →
  136. 2026FDA removes LL-37 from its Category 2 compounding list pending advisory review planned before end of February 2027 LL-37 →
  137. 2026FDA removes PEG-MGF from its Category 2 compounding list (April) MGF (Mechano Growth Factor) and PEG-MGF →
  138. 2026FDA PCAC votes 7–5 to recommend MOTS-c for the 503A bulks list (July) MOTS-c →
  139. 2026FDA advisory committee votes 8–6–1 on TB-500 compounding; no final FDA decision as of 22 Oct 2026 TB-500 →
  140. 2026FDA Pharmacy Compounding Advisory Committee votes 6–7 against emideltide (DSIP) for the 503A bulks list (July) DSIP →
  141. 2026FDA Pharmacy Compounding Advisory Committee votes 8–5 in favor of Semax for the 503A bulks list (July; advisory only) Semax →
  142. 2026FDA removes dihexa acetate from Category 2 in April and schedules advisory committee review before end of February 2027 Dihexa →
  143. 2026FDA removes Melanotan II from its Category 2 compounding list and schedules PCAC review before the end of February 2027 Melanotan II →
  144. 2026FDA approves orforglipron as Foundayo, the first new molecular entity under the National Priority Voucher pilot (1 Apr 2026) Orforglipron →
  145. 2026Lilly completes its initial TRIUMPH Phase 3 program and plans a US submission for Q1 2027; not FDA-approved as of Oct 2026 Retatrutide →
  146. 2026FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list (30 Apr 2026) Semaglutide →
  147. 2026Anti-doping laboratory in Cologne publishes in vitro metabolism study of SLU-PP-332 SLU-PP-332 →
  148. 2027FDA PCAC review of PEG-MGF scheduled before end of February MGF (Mechano Growth Factor) and PEG-MGF →

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

Frequently asked questions

What does the research peptide timeline cover?

Key dates in the discovery, development and regulation of every compound in the Kalibra Labs catalog, from the first synthetic peptide hormones to the 2026 FDA compounding reviews. Each entry links to the compound’s full reference page.

Why are some dates patent or publication years?

Many research peptides were first disclosed in patents or journal papers rather than product launches, so the earliest documented date is used and cited on the compound page.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top